Experimental pancreatic cancer drug yields sizable survival gain in Phase 3, signaling potential rapid FDA approval

Revolution Medicines reported that its daily pill daraxonrasib produced a median overall survival of 13.2 months in a Phase 3 trial for advanced pancreatic adenocarcinoma, compared with 6.7 months for standard chemotherapy, a notable survival boost that could accelerate an FDA submission, with trial investigators like NYU Langone’s Paul Oberstein discussing the implications on The Readout Loud podcast.